undamentalytics Newsletter
Sign in

Vir Biotechnology, Inc. balance sheet

At the end of fiscal 2025, Vir Biotechnology, Inc. had total assets of $1.00bn, total liabilities of $238m and shareholders' equity of $765m. It held $232m in cash against $0 of debt: net cash of $232m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents18848109437348849242223232279
Receivables———07730————
Total current assets—1184037721,5632,5191,5881,042514574
Goodwill—171717171717171717
Total assets—1925129191,9542,8021,9191,3991,0031,215
Accounts payable—66576651018
Deferred revenue (current)—966981665130—
Total current liabilities—4059993415111751209395
Total debt0000000000
Total liabilities—6288202522724329248238232
Shareholders' equity−69−1794247171,4322,0781,5901,150765982
Non-controlling interests and other (assets − liabilities − equity)—309————————
Net debt (negative = net cash)−188−48−109−437−348−849−242−223−232−279
Shares outstanding—133m108m127m131m133m135m137m139m169m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: VCEL vs VIRADPT vs VIRARVN vs VIRSNDX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vir Biotechnology, Inc.